NASDAQ$IDYA
IDEAYA Biosciences Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
IDEAYA Biosciences reported financial results for Q4 and full year 2023 and provided a business update.
IDEAYA Biosciences reported a net loss of $34.0 million for the fourth quarter of 2023, compared to a net loss of $24.2 million for the same period in 2022. The company's cash, cash equivalents, and marketable securities totaled $632.6 million as of December 31, 2023, which, supplemented by net proceeds from January 2024 ATM offerings, is expected to fund operations into 2028.
- Targeting two independent Phase 2 clinical efficacy updates for darovasertib in neoadjuvant uveal melanoma (UM) in mid-2024.
- Targeting FDA regulatory guidance on darovasertib in neoadjuvant UM indication in 2024.
- Established clinical study collaboration with Gilead Sciences to evaluate IDE397 and Trodelvy® combo in MTAP bladder cancer with FPI targeted for mid-year 2024.
- Cash balance of $632.6 million as of December 31, 2023, supplemented by net proceeds of $342.3 million from January 2024 ATM offerings, expected to fund operations into 2028.
Headline financials
Revenue & EPS history
IDEAYA · Revenue · Quarterly
$3.92M
Revenue by segment
IDEAYA · $8.04M total across 1 segment · Q3 2023
- Collaboration Revenue$8.04M—100.0%
Forward guidance
IDEAYA is focused on advancing its clinical programs and achieving key milestones in 2024, including clinical efficacy updates, regulatory guidance, and IND filings, while also expanding its pipeline of precision medicine candidates.
Tailwinds
- Targeting two independent Phase 2 clinical efficacy updates for darovasertib in neoadjuvant uveal melanoma (UM) in mid-2024.
- Targeting FDA regulatory guidance on darovasertib in neoadjuvant UM indication in 2024.
- Ongoing enrollment of IDE397 and AMG 193 Phase 1 combo in MTAP solid tumors and targeting development of joint Amgen / IDEAYA publication strategy in 2024.
- Established clinical study collaboration with Gilead Sciences to evaluate IDE397 and Trodelvy® combo in MTAP bladder cancer with FPI targeted for mid-year 2024.
- Targeting IDE161 clinical program update(s) and enabling of clinical combination(s) in 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
+1.4%
Avg return
Earnings day
+2.1%
Avg return
5 days after
+6.7%
Avg return
30 days after
52%
14 / 27 earnings
Positive
+40.5%
Q3 2019
Best reaction
-31.4%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.3% | -1.9% | +1.2% | |
| Q4 2025 | +1.6% | +5.6% | +7.7% | |
| Q3 2025 | -2.7% | -3.6% | +14.8% | |
| Q1 2025 | +2.9% | +10.6% | +28.1% | |
| Q4 2024 | -5.4% | -6.9% | -15.4% | |
| Q3 2024 | +3.4% | +9.4% | -0.9% | |
| Q2 2024 | -3.1% | +2.4% | +1.0% | |
| Q1 2024 | -3.9% | -4.5% | -8.0% | |
| Q4 2023 | -6.0% | -2.7% | -3.2% | |
| Q3 2023 | +6.9% | +1.6% | +8.1% | |
| Q2 2023 | +1.2% | +3.3% | +12.9% | |
| Q1 2023 | +15.6% | +10.2% | +31.5% | |
| Q4 2022 | +2.1% | -8.7% | -16.0% | |
| Q3 2022 | -3.4% | -1.8% | -2.5% | |
| Q2 2022 | -31.4% | -34.8% | -20.1% | |
| Q1 2022 | +13.0% | +26.4% | +48.4% | |
| Q4 2021 | -2.2% | +3.8% | -11.1% | |
| Q3 2021 | +3.9% | +0.8% | -4.1% | |
| Q2 2021 | -3.5% | +1.0% | +14.1% | |
| Q1 2021 | +7.8% | +1.7% | +12.5% | |
| Q4 2020 | -8.2% | -2.8% | -15.9% | |
| Q3 2020 | +2.5% | +6.3% | +9.3% | |
| Q2 2020 | -1.2% | -1.7% | +4.8% | |
| Q1 2020 | -9.4% | -0.6% | -5.3% | |
| Q4 2019 | +13.6% | +14.9% | +40.8% | |
| Q3 2019 | +40.5% | +30.6% | +29.6% | |
| Q2 2019 | +6.0% | -1.5% | +19.6% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro